Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28443003 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3182791 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL31395676 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3177549 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL15500293 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL313703 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL16329524 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL16329522 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL21479469 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL2048089 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4563586-A1 | NEW INHIBITORS OF LRRK2/PP1 INTERACTION | Université Paris Cité (FR) | 2025-06-04 | — | — | EP | claimed |
| CN-118326399-A | Low-scratch and easy-to-clean tungsten plug chemical mechanical polishing solution and application thereof | 万华化学集团电子材料有限公司 | 2024-07-12 | — | — | CN | claimed |
| EP-4728279-A2 | USE OF CUSTOM-DESIGNED PEPTIDES FOR MASS CALIBRATION | DH Technologies Development Pte. Ltd. (SG) | 2026-04-22 | — | — | EP | disclosed |
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| EP-4563586-A1 | NEW INHIBITORS OF LRRK2/PP1 INTERACTION | Université Paris Cité (FR) | 2025-06-04 | — | — | EP | disclosed |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | TRIPARTITE THERAPEUTICS INC. (TW) | 2025-01-30 | — | — | US | disclosed |
| WO-2024257055-A2 | USE OF CUSTOM-DESIGNED PEPTIDES FOR MASS CALIBRATION | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2024-12-19 | — | — | WO | disclosed |
| US-12037641-B2 | Modified nucleotide reagents | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118326399-A | Low-scratch and easy-to-clean tungsten plug chemical mechanical polishing solution and application thereof | 万华化学集团电子材料有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11827624-B2 | Covalent immune recruiter compounds for immune cell recognition and associated uses | MCMASTER UNIVERSITY (CA) | 2023-11-28 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
| US-20130336920-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2590656-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2591354-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20130052130-A1 | Branched Discreet PEG Constructs | UNIVERSITY OF WASHINGTON (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2012054110-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037641-B2 | Modified nucleotide reagents | POLL, POLN, POLM | MEN1 4374/4885KMT2A 2859/4885TSHR 3276/4885 |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | MEN1 2404/4885KMT2A 4695/4885TSHR 3105/4885 |
| US-11827624-B2 | Covalent immune recruiter compounds for immune cell recognition and associated uses | CD74, CD4, HLA-A | MEN1 4065/4885KMT2A 3495/4885TSHR 2277/4885 |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | MEN1 3183/4885KMT2A 4830/4885TSHR 4326/4885 |
| US-20130336920-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | MEN1 2404/4885KMT2A 4695/4885TSHR 3105/4885 |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | MEN1 3081/4885KMT2A 778/4885TSHR 4150/4885 |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | CD274, SELPLG, PDCD1LG2 | MEN1 2090/4885KMT2A 4242/4885TSHR 648/4885 |
| US-20130052130-A1 | Branched Discreet PEG Constructs | BTD, DNPEP, IDUA | MEN1 3511/4885KMT2A 2440/4885TSHR 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.